Chief Technology Officer @ (January 2022 - August 2023)
Senior Vice President Drug Discovery and Development @ Cygnal Therapeutics (November 2020 - November 2021)
Vice President Biologics Drug Development @ Cygnal Therapeutics (July 2019 - October 2020)
Director Biology, Discovery Partnerships with Academia @ (January 2016 - June 2019)
Director Biology, Virtual Proof of Concept @ (November 2013 - December 2015)
Director -Biologics Strategy, Cardiovascular Diseases @ Merck & Co, Inc (November 2004 - October 2013)
Postdoctoral fellow @ (January 2001 - January 2004)
Postdoctoral Fellow @ (January 1999 - January 2001)
Daniël Blom Education
University of Amsterdam
PhD (Biochemistry)
1994-1999
University of Amsterdam
MSc (Chemistry)
1989-1993
Daniël Blom Skills
Antibodies
Biochemistry
Biomarkers
Biotechnology
Drug Development
Drug Discovery
In Vitro
Lifesciences
Molecular Biology
Monoclonal Antibodies
Oncology
Pharmaceutical Industry
Pharmaceutics
Business Development
Marketing
Public Speaking
Daniël Blom Summary
Daniël Blom, based in Boston, MA, US, is currently a Chief Scientific Officer at Ampersand Biomedicines. Daniël Blom brings experience from previous roles at Ampersand Biomedicines, Cygnal Therapeutics and GSK. Daniël Blom holds a 1994 - 1999 PhD in Biochemistry @ University of Amsterdam. With a robust skill set that includes Antibodies, Biochemistry, Biomarkers, Biotechnology, Drug Development and more. Daniël Blom has 2 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Daniël Blom?
Find contact details for 700 million professionals.